Literature DB >> 15614524

Discriminate gene lists derived from cDNA microarray profiles of limited samples permit distinguishing mesenchymal neoplasia ex vivo.

David E Joyner1, Mark L Wade, Aniko Szabo, Jeffrey Bastar, Cheryl M Coffin, Karen H Albritton, Philip S Bernard, R Lor Randall.   

Abstract

BACKGROUND: Mesenchymal neoplasia comprises a heterogeneous group of tumors with over 200 benign neoplasms and 100 sarcomas. Currently, tumors are classified using histologic and immunocytologic characteristics, with diagnostic error rates reported as high as 40% of cases. As a feasibility study, our goal was to generate a preliminary discriminatory gene list for selected mesenchymal tumors, including sarcomas. This technique may enable an eventual molecular classification schema based on expression profiles that can complement current clinical and pathologic diagnostic procedures in mesenchymal tumors.
METHODS: cDNA microarray analyses were preformed on connective tissue tumors obtained at time of surgical resection or biopsy. Messenger RNA (mRNA) from four general tumor classes was competitively hybridized against a human dermal fibroblast cell line comparator and the resulting gene expression profiles processed by ANOVA and linear discriminate analysis.
RESULTS: The tissue classification involved 18 patients with malignant peripheral nerve sheath tumors, giant cell containing tumors, benign spindle cell lesions, or Ewing's family of tumors. Lymph nodes from two patients served comparative purposes. Twenty-five differentially regulated genes considered most variable among the five tissue classes were identified. The tissues were segregated into five classes by linear discriminate analysis.
CONCLUSIONS: Linear discriminate analysis of cDNA gene expression profiles partitioned mesenchymal tumor classes, even when constrained by limited sample sizes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15614524     DOI: 10.1007/s00432-004-0640-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  39 in total

Review 1.  Cell signaling by receptor tyrosine kinases.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

2.  Variable selection and pattern recognition with gene expression data generated by the microarray technology.

Authors:  A Szabo; K Boucher; W L Carroll; L B Klebanov; A D Tsodikov; A Y Yakovlev
Journal:  Math Biosci       Date:  2002-03       Impact factor: 2.144

3.  Validation of cDNA microarray analysis to distinguish tumor type ex vivo.

Authors:  R Lor Randall; Mark Wade; Karen H Albritton; Cheryl M Coffin; David E Joyner
Journal:  Clin Orthop Relat Res       Date:  2003-10       Impact factor: 4.176

4.  Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays.

Authors:  Spyro Mousses; Lukas Bubendorf; Urs Wagner; Galen Hostetter; Juha Kononen; Robert Cornelison; Natalie Goldberger; Abdel G Elkahloun; Niels Willi; Pasi Koivisto; William Ferhle; Mark Raffeld; Guito Sauter; Olli-P Kallioniemi
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

5.  Lecithin-cholesterol acyltransferase (LCAT) catalyzes transacylation of intact cholesteryl esters. Evidence for the partial reversal of the forward LCAT reaction.

Authors:  M Sorci-Thomas; J Babiak; L L Rudel
Journal:  J Biol Chem       Date:  1990-02-15       Impact factor: 5.157

6.  Cell surface tumor endothelial markers are conserved in mice and humans.

Authors:  E B Carson-Walter; D N Watkins; A Nanda; B Vogelstein; K W Kinzler; B St Croix
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

7.  Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency.

Authors:  B D Gelb; G P Shi; H A Chapman; R J Desnick
Journal:  Science       Date:  1996-08-30       Impact factor: 47.728

8.  Molecular characterisation of soft tissue tumours: a gene expression study.

Authors:  Torsten O Nielsen; Rob B West; Sabine C Linn; Orly Alter; Margaret A Knowling; John X O'Connell; Shirley Zhu; Mike Fero; Gavin Sherlock; Jonathan R Pollack; Patrick O Brown; David Botstein; Matt van de Rijn
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

9.  Increasing single epirubicin doses in advanced soft tissue sarcomas.

Authors:  Massimo Lopez; Patrizia Vici; Luigi Di Lauro; Silvia Carpano
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

10.  Consultative (expert) second opinions in soft tissue pathology. Analysis of problem-prone diagnostic situations.

Authors:  Z K Arbiser; A L Folpe; S W Weiss
Journal:  Am J Clin Pathol       Date:  2001-10       Impact factor: 2.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.